Oxaliplatin for injection
Function and Efficacy
This product is a new platinum derivative, the central platinum atom is surrounded by oxalic acid and 1.2-diaminocyclohexane, in a trans conformation, and is a stereoisomer. Like other platinum derivatives, oxaliplatin acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. Oxaliplatin binds to DNA rapidly, taking up to 15 minutes, while cisplatin binds to DNA in two phases, including a delayed phase after 48 hours. One hour after administration in the human body, its presence can be shown by measuring adducts in white blood cells. DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective in some cell lines that are resistant to cisplatin.
Ingredients
The main ingredient of this product is oxaliplatin. Its chemical name is: (1R-trans)-(1,2-cyclohexanediamine-N,N)[oxalate (Z-)-O,O]platinum.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| OxaliplatinIngredients |
Oxaliplatin is a new platinum derivative that acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. Oxaliplatin binds to DNA rapidly, taking up to 15 minutes. DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective in some cell lines that are resistant to cisplatin. More |
61825-94-3 | 56 |
Indication
1. This product is a normal cell protective agent, mainly used for the adjuvant treatment of various cancers; 2. The use of this product before chemotherapy for patients with various cancers such as lung cancer, ovarian cancer, breast cancer, nasopharyngeal cancer, bone tumors, digestive tract tumors, and blood system tumors can significantly reduce the toxicity of chemotherapy drugs to the kidneys, bone marrow, heart, ears, and nervous systems without reducing the efficacy of chemotherapy drugs; 3. The use of this product before radiotherapy can significantly reduce the occurrence of dry mouth and mucositis.
Usage and Dosage
When used alone or in combination, the recommended dose is 130 mg/m2, added to 250-500 ml of 5% glucose solution and infused for 2-6 hours. When no major toxicity occurs, the drug is administered once every 3 weeks (21 days). Dose adjustment should be based on safety, especially neurological safety.
Adverse Reactions
1. The main adverse reactions in hematology are: anemia, leukopenia, granulocytopenia and thrombocytopenia. 2. The main adverse reactions in non-hematology are: nausea, vomiting, diarrhea. 3. Nervous system: The main manifestation is peripheral neuritis, sometimes there may be spasms and sensory disorders around the mouth, upper respiratory tract and upper digestive tract.
Precautions
1. Use with caution in patients with hypotension and hypocalcemia; 2. Contraindicated in patients with a history of allergy to this product or allergic to mannitol.
Drug Interactions
This trial has not been conducted and there are no reliable references.
Storage
Sealed and stored below 25°C.
Packaging Specification
50mg
Manufacturer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
-
Founded in:
1992-12-31 -
Address:
No. 866, Moganshan Road, Gongshu District, Hangzhou City, Zhejiang Province -
Tax NO.:
91330100609120774J -
Registered Funds:
872.30813 million yuan -
Website:
-
Email: